無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

欧州の整形外科用バイオマテリアル市場の概要

Europe Market Overview for Orthopedic Biomaterials 2017 - MedView

発行 iData Research Inc. 商品コード 524556
出版日 ページ情報 英文 190 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.49円で換算しております。

※ Single Userライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
認証されたPC上のみでの閲覧となっております。

Back to Top
欧州の整形外科用バイオマテリアル市場の概要 Europe Market Overview for Orthopedic Biomaterials 2017 - MedView
出版日: 2017年06月01日 ページ情報: 英文 190 Pages
概要

当レポートでは、欧州の整形外科用バイオマテリアル市場について調査分析し、市場概要、国別プロファイル、動向分析、促進要因・阻害要因、競合分析など、体系的な情報を提供しています。

エグゼクティブサマリー

欧州の整形外科用バイオマテリアル市場:概要

競合分析

市場動向

市場の発展

対象市場

主な調査アップデート

バージョン履歴

第1章 調査手法

第2章 疾患の概要

  • 基本構造
  • 疾患の病状・障害
  • 患者の人口統計

第3章 国別プロファイル

  • イントロダクション
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ベネルクス諸国
  • 北欧諸国
  • オーストリア
  • スイス
  • ポルトガル

第4章 欧州の整形外科用バイオマテリアル市場の概要

  • イントロダクション
  • 為替レート
  • 市場の概要
  • 動向分析:セグメント別
  • 促進要因・阻害要因
    • 市場促進要因
    • 市場阻害要因
  • 競合市場シェア分析
  • M&A
  • 企業プロファイル
  • SWOT分析

略語

付録

目次
Product Code: iDATA_EUOB17_MV

The full report suite on the U.S.European market for orthopedic biomaterials includes bone graft substitutes, which is represented by allografts, demineralized bone matrix and synthetic bone graft market. The report also includes hyaluronic acid viscosupplementation, orthopedic growth factors, orthopedic cell therapy, orthopedic cartilage repair and spinal machined bone allograft markets.

General Report Contents:

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions

Lack of reimbursements can limit the European orthopedic biomaterials market. When a product is reimbursed, it is more readily adopted. For instance, in the hyaluronic acid market, most products are classified as medical devices and thus are not eligible for reimbursement. Only a few premium products under the umbrella of pharmaceuticals are reimbursed by the government or healthcare organizations. In addition to not being as well received as reimbursed products, the lack of reimbursement drives pricing down in an effort to make them more affordable. This price deterioration will have a negative impact on the market, as it may not be economically feasible for certain competitors to penetrate a market with low ASPs.

Unlike donated material, synthetic bone graft materials do not carry the risk of disease transmission, nor will they generate an immunogenic response in the recipient. As with allograft, the use of synthetic materials avoids the need for a second bone harvesting procedure. These products have been steadily reducing the amount of autograft bone that doctors have been using. Popularity of synthetics due to the affordability and easy accessibility, synthetic products are becoming the preferred products over allografts, DBMs and autografts. A wide range of synthetic products can offer flexibility and variety for different groups of patients. People in general are becoming more knowledgeable and accepting of synthetic products.

TABLE OF CONTENTS

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

COMPETITIVE ANALYSIS

MARKET TRENDS

MARKET DEVELOPMENTS

MARKETS INCLUDED

KEY REPORT UPDATES

VERSION HISTORY

RESEARCH METHODOLOGY

  • 1.1. RESEARCH SCOPE
  • 1.2. IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

DISEASE OVERVIEW

  • 2.1. BASIC ANATOMY
    • 2.1.1. Osteology and Musculoskeletal System
  • 2.2. DISEASE PATHOLOGY AND DISORDERS
    • 2.2.1. General Diagnostic
    • 2.2.2. Osteoporosis
    • 2.2.3. Osteoarthritis
    • 2.2.4. Indication for Bone Graft Procedure
    • 2.2.5. Indication for Cartilage Repair
    • 2.2.6. Degenerative Disc Disease
  • 2.3. PATIENT DEMOGRAPHICS
    • 2.3.1. General Statistics

COUNTRY PROFILES

  • 3.1. INTRODUCTION
    • 3.1.1. Population
    • 3.1.2. GDP Per Capita
    • 3.1.3. Price Index
  • 3.2. GERMANY
  • 3.3. FRANCE
  • 3.4. UNITED KINGDOM
  • 3.5. ITALY
  • 3.6. SPAIN
  • 3.7. BENELUX
  • 3.8. SCANDINAVIA
  • 3.9. AUSTRIA
  • 3.10. SWITZERLAND
  • 3.11. PORTUGAL

EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

  • 4.1. INTRODUCTION
    • 4.1.1. Bone Graft Substitutes
    • 4.1.2. Growth Factors
    • 4.1.3. Hyaluronic Acid Viscosupplementation
    • 4.1.4. Autologous Chondrocyte Implantation
    • 4.1.5. Cell Therapies
  • 4.2. CURRENCY EXCHANGE RATE
  • 4.3. MARKET OVERVIEW
  • 4.4. TREND ANALYSIS BY SEGMENT
  • 4.5. DRIVERS AND LIMITERS
    • 4.5.1. Market Drivers
    • 4.5.2. Market Limiters
  • 4.6. COMPETITIVE MARKET SHARE ANALYSIS
  • 4.7. MERGERS AND ACQUISITIONS
  • 4.8. COMPANY PROFILES
    • 4.8.1. Anika Therapeutics
    • 4.8.2. Bioventus
    • 4.8.3. DePuy Synthes
    • 4.8.4. Ferring Pharmaceuticals
    • 4.8.5. Fidia Pharmaceuticals
    • 4.8.6. Genzyme (Sanofi Group)
    • 4.8.7. Harvest Technologies (Terumo BCT)
    • 4.8.8. Integra LifeSciences
    • 4.8.9. Medtronic
    • 4.8.10. Musculoskeletal Transplant Foundation (MTF)
    • 4.8.11. NuVasive
    • 4.8.12. Orthofix
    • 4.8.13. RTI Surgical
    • 4.8.14. Vericel Corporation (formerly Aastrom Bioscience)
    • 4.8.15. Stryker
    • 4.8.16. Zimmer Biomet
  • 4.9. SWOT ANALYSIS
    • 4.9.1. Anika Therapeutics
    • 4.9.2. Bioventus
    • 4.9.3. DePuy Synthes
    • 4.9.4. Ferring Pharmaceuticals
    • 4.9.5. Fidia Pharmaceuticals
    • 4.9.7. Harvest Technologies (Terumo BCT)
    • 4.9.8. Integra LifeScience
    • 4.9.9. Medtronic
    • 4.9.10. Musculoskeletal Transplant Foundation (MTF)
    • 4.9.11. NuVasive
    • 4.9.12. Orthofix
    • 4.9.14. Vericel Corporation (formerly Aastrom Bioscience)
    • 4.9.15. Stryker
    • 4.9.16. Zimmer Biomet

ABBREVIATIONS

APPENDIX III: COMPANY PRESS RELEASES

LIST OF CHARTS

  • Chart 1 1: Orthopedic Biomaterials Market by Segment, Europe, 2013 - 2023
  • Chart 1 2: Orthopedic Biomaterials Market Overview, Europe, 2016 & 2023
  • Chart 3 1: Country Profile, Germany, 2016
  • Chart 3 2: Country Profile, France, 2016
  • Chart 3 3: Country Profile, United Kingdom, 2016
  • Chart 3 4: Country Profile, Italy, 2016
  • Chart 3 5: Country Profile, Spain, 2016
  • Chart 3 6: Country Profile, Benelux, 2016
  • Chart 3 7: Country Profile, Scandinavia, 2016
  • Chart 3 8: Country Profile, Austria, 2016
  • Chart 3 9: Country Profile, Switzerland, 2016
  • Chart 3 10: Country Profile, Portugal, 2016
  • Chart 4 1: Orthopedic Biomaterials Market by Segment, Europe, 2013 - 2023
  • Chart 4 2: Orthopedic Biomaterials Market Breakdown, Europe, 2016
  • Chart 4 3: Orthopedic Biomaterials Market Breakdown, Europe, 2023
  • Chart 4 4: Growth Rates by Segment, Orthopedic Biomaterials Market, Europe, 2013 - 2023
  • Chart 4 5: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2016

LIST OF FIGURES

  • Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, Europe, 2016
  • Figure 1 2: Companies Researched in this Report, Europe, 2016
  • Figure 1 3: Factors Impacting the Orthopedic Biomaterials Market by Segment, Europe
  • Figure 1 4: Recent Events in the Orthopedic Biomaterials Market, Europe, 2015 - 2016
  • Figure 1 5: Orthopedic Biomaterials Markets Covered, Europe, 2016 (1 of 2)
  • Figure 1 6: Orthopedic Biomaterials Markets Covered, Europe, 2016 (2 of 2)
  • Figure 1 7: Key Report Updates
  • Figure 1 8: Version History
  • Figure 4 1: Currency Exchange Rate, 2016
  • Figure 4 2: Orthopedic Biomaterials Market by Segment, Europe, 2013 - 2023 (€M)
  • Figure 4 3: Orthopedic Biomaterials Market by Segment, Europe, 2013 - 2023 (US$M)
  • Figure 4 4: Orthopedic Biomaterials Market Growth by Segment, Europe, 2013 - 2023
  • Figure 4 5: Drivers and Limiters, Orthopedic Biomaterials Market, Europe, 2016
  • Figure 4 6: Leading Competitors, Orthopedic Biomaterials Market, Europe, 2016
  • Figure 4 7: SWOT Analysis, Anika Therapeutics, 2017
  • Figure 4 8: SWOT Analysis, Bioventus, 2017
  • Figure 4 9: SWOT Analysis, DePuy Synthes, 2017
  • Figure 4 10: SWOT Analysis, Ferring Pharmaceuticals, 2017
  • Figure 4 11: SWOT Analysis, Fidia Pharmaceuticals, 2017
  • Figure 4 12: SWOT Analysis, Genzyme (Sanofi), 2017
  • Figure 4 13: SWOT Analysis, Harvest Technologies, 2017
  • Figure 4 14: SWOT Analysis, Integra LifeScience, 2017
  • Figure 4 15: SWOT Analysis, Medtronic, 2017
  • Figure 4 16: SWOT Analysis, MTF, 2017
  • Figure 4 17: SWOT Analysis, NuVasive, 2017
  • Figure 4 18: SWOT Analysis, Orthofix, 2017
  • Figure 4 19: SWOT Analysis, RTI Surgical, 2017
  • Figure 4 20: SWOT Analysis, Vericel Corporation, 2017
  • Figure 4 21: SWOT Analysis, Stryker, 2017
  • Figure 4 22: SWOT Analysis, Zimmer Biomet, 2017 (1 of 2)
  • Figure 4 23: SWOT Analysis, Zimmer Biomet, 2017 (2 of 2)
  • Figure 6 1: Press Release Summary
Back to Top